Compare SAP SE (SAP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs Vertex Pharmaceuticals Incorporated — how do they compare? SAP SE trades at $203.72 (market cap $240.81B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B). The key difference: SAP SE is the larger of the two by market cap, and SAP SE pays a 1.4% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SAP | VRTX | |
|---|---|---|
Market Cap | $240.81B | $134.25B |
Sector | Technology | Health |
52-Week High | $280.46 | $529.65 |
52-Week Low | $146.38 | $376.62 |
Enterprise Value | $239.52B | $128.37B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAP trades at $204.035, down 2.16% today, with a bullish technical trend supported by moving averages but overbought RSI signals. Revenue grew to $36.8B in 2025 with a strong net income margin of 20.41%, though Q2 2026 EPS missed estimates. Recent news highlights AI and cloud momentum, with shares reacting positively to Q2 results despite profit guidance concerns.
Outlook is cautiously optimistic with a consensus price target of $209.67, offering modest upside. Risks include execution challenges in AI integration and margin pressure from rising costs. The stock presents a growth opportunity driven by cloud adoption, but investors should weigh valuation multiples against earnings consistency.
Vertex Pharmaceuticals (VRTX) trades at $525.72, up 0.35% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales guidance, driven by cystic fibrosis drug strength and new product contributions. Profitability remains robust with a 35% net income margin, though the P/E ratio of 30.85 reflects premium valuation.
Outlook is positive with 84% analyst buy ratings and a $534.25 consensus target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of new launches and sustained CF franchise growth, while any clinical or regulatory setbacks could pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
